Secreted mucins in pseudomyxoma peritonei: pathophysiological significance and potential therapeutic prospects

Orphanet Journal of Rare Diseases

David Lawson Morris¹  Anahid Ehteda¹  Samar Masoumi-Moghaddam¹  Afshin Amini¹ 

[1] Department of Surgery, St George Hospital, The University of New South Wales, Level 3, Clinical Sciences (WR Pitney) Building, Gray Street, Kogarah, Sydney, NSW 2217, Australia

关键词: Appendix;    Goblet cells;    MUC2;    Mucin;    PMP;    Pseudomyxoma peritonei;   

Others  :  861771
DOI  :  10.1186/1750-1172-9-71

 received in 2014-02-28, accepted in 2014-04-22,  发布年份 2014

【 摘 要 】

Pseudomyxoma peritonei (PMP, ORPHA26790) is a clinical syndrome characterized by progressive dissemination of mucinous tumors and mucinous ascites in the abdomen and pelvis. PMP is a rare disease with an estimated incidence of 1–2 out of a million. Clinically, PMP usually presents with a variety of unspecific signs and symptoms, including abdominal pain and distention, ascites or even bowel obstruction. It is also diagnosed incidentally at surgical or non-surgical investigations of the abdominopelvic viscera. PMP is a neoplastic disease originating from a primary mucinous tumor of the appendix with a distinctive pattern of the peritoneal spread. Computed tomography and histopathology are the most reliable diagnostic modalities. The differential diagnosis of the disease includes secondary peritoneal carcinomatoses and some rare peritoneal conditions. Optimal elimination of mucin and the mucin-secreting tumor comprises the current standard of care for PMP offered in specialized centers as visceral resections and peritonectomy combined with intraperitoneal chemotherapy. This multidisciplinary approach has reportedly provided a median survival rate of 16.3 years, a median progression-free survival rate of 8.2 years and 10- and 15-year survival rates of 63% and 59%, respectively. Despite its indolent, bland nature as a neoplasm, PMP is a debilitating condition that severely impacts quality of life. It tends to be diagnosed at advanced stages and frequently recurs after treatment. Being ignored in research, however, PMP remains a challenging, enigmatic entity. Clinicopathological features of the PMP syndrome and its morbid complications closely correspond with the multifocal distribution of the secreted mucin collections and mucin-secreting implants. Novel strategies are thus required to facilitate macroscopic, as well as microscopic, elimination of mucin and its source as the key components of the disease. In this regard, MUC2, MUC5AC and MUC5B have been found as the secreted mucins of relevance in PMP. Development of mucin-targeted therapies could be a promising avenue for future research which is addressed in this article.

【 授权许可】

   
2014 Amini et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Smeenk RM, van Velthuysen ML, Verwaal VJ, Zoetmulder FA: Appendiceal neoplasms and pseudomyxoma peritonei: a population based study. Eur J Surg Oncol 2008, 34:196-201.
• [2]The portal for rare diseases and orphan drugs [http://www.orpha.net/consor/cgi-bin/index.php?lng=EN webcite]
• [3]Werth R: Klinische und anatomische untersuchungen zur lehre von den bauchgeschwülsten und der laparatomie. Archiv Fur Gynakologie 1884, 24:100-118.
• [4]Fraenkel E: Ueber das sogennante pseudomyxoma perotonei. Munch Med Wochenschr 1901, 48:965-971.
• [5]Ronnett BM, Zahn CM, Kurman RJ, Kass ME, Sugarbaker PH, Shmookler BM: Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to “pseudomyxoma peritonei”. Am J Surg Pathol 1995, 19:1390-1408.
• [6]Sugarbaker PH: Pseudomyxoma peritonei. Cancer Treat Res 1996, 81:105-119.
• [7]Ronnett BM, Yan H, Kurman RJ, Shmookler BM, Wu L, Sugarbaker PH: Patients with pseudomyxoma peritonei associated with disseminated peritoneal adenomucinosis have a significantly more favorable prognosis than patients with peritoneal mucinous carcinomatosis. Cancer 2001, 92:85-91.
• [8]O’Connell JT, Tomlinson JS, Roberts AA, McGonigle KF, Barsky SH: Pseudomyxoma peritonei is a disease of MUC2-expressing goblet cells. Am J Pathol 2002, 161:551-564.
• [9]Misdraji J: Appendiceal mucinous neoplasms: controversial issues. Arch Pathol Lab Med 2010, 134:864-870.
• [10]Buell-Gutbrod R, Gwin K: Pathologic diagnosis, origin, and natural history of pseudomyxoma peritonei. Am Soc Clin Oncol Educ Book 2013, 33:221-225.
• [11]Sugarbaker PH: Pseudomyxoma peritonei. A cancer whose biology is characterized by a redistribution phenomenon. Ann Surg 1994, 219:109-111.
• [12]Sugarbaker PH: New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol 2006, 7:69-76.
• [13]Lohani K, Shetty S, Sharma P, Govindarajan V, Thomas P, Loggie B: Pseudomyxoma Peritonei: Inflammatory Responses in the Peritoneal Microenvironment. Ann Surg Oncol 2014, 21:1441-1447.
• [14]Pseudomyxoma peritonei [http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN&Expert=26790 webcite]
• [15]Chua TC, Moran BJ, Sugarbaker PH, Levine EA, Glehen O, Gilly FN, Baratti D, Deraco M, Elias D, Sardi A, Liauw W, Yan TD, Barrios P, Gómez Portilla A, de Hingh IH, Ceelen WP, Pelz JO, Piso P, González-Moreno S, Van Der Speeten K, Morris DL: Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol 2012, 30:2449-2456.
• [16]Smeenk RM, Bruin SC, van Velthuysen ML, Verwaal VJ: Pseudomyxoma peritonei. Curr Probl Surg 2008, 45:527-575.
• [17]Sugarbaker PH, Ronnett BM, Archer A, Averbach AM, Bland R, Chang D, Dalton RR, Ettinghausen SE, Jacquet P, Jelinek J, Koslowe P, Kurman RJ, Shmookler B, Stephens AD, Steves MA, Stuart OA, White S, Zahn CM, Zoetmulder FA: Pseudomyxoma peritonei syndrome. Adv Surg 1996, 30:233-280.
• [18]Esquivel J, Sugarbaker PH: Clinical presentation of the Pseudomyxoma peritonei syndrome. Br J Surg 2000, 87:1414-1418.
• [19]Ben-Hur H, Schachter M, Mashiah A, Lifschitz-Mercer B, Pfeffermann R: Recurrent mucinous adenocarcinoma of the ovary presenting as an inguino-labial hernia. Eur J Gynaecol Oncol 1996, 17:299-302.
• [20]Young RH, Rosenberg AE, Clement PB: Mucin deposits within inguinal hernia sacs: a presenting finding of low-grade mucinous cystic tumors of the appendix. A report of two cases and a review of the literature. Mod Pathol 1997, 10:1228-1232.
• [21]Edwards DP, Scott HJ: The use of laparoscopy in a case of appendiceal cystadenoma presenting as pseudomyxoma peritonei in an inguinal hernial sac. J R Coll Surg Edinb 1998, 43:112-113.
• [22]Esquivel J, Sugarbaker PH: Pseudomyxoma peritonei in a hernia sac: analysis of 20 patients in whom mucoid fluid was found during a hernia repair. Eur J Surg Oncol 2001, 27:54-58.
• [23]Rezkalla MA, Peterson KG, Ryan JJ: Pseudomyxoma peritonei: a case of mucinous adenocarcinoma of the appendix presenting as inguinal hernia. S D Med 2006, 59:54-55. 57
• [24]Shinohara T, Misawa K, Sano H, Okawa Y, Takada A: Pseudomyxoma peritonei due to mucinous cystadenocarcinoma in situ of the urachus presenting as an inguinal hernia. Int J Clin Oncol 2006, 11:416-419.
• [25]Campbell P, Dawson S, Wali J, Kenny B, Whiteside MC: Pseudomyxoma peritonei presenting as inguinal hernia. Ulster Med J 2009, 78:189-190.
• [26]Ghidirim G, Mishin I, Zastavnitsky G: Pseudomyxoma peritonei presenting with inguinal hernia. Chirurgia (Bucur) 2011, 106:527-529.
• [27]Morris-Stiff G, Falk GA, Joyce D, Chalikonda S: Unusual contents of a scrotal swelling. BMJ case reports 2011., 2011doi:10.1136/bcr.03.2011.4023
• [28]Skaane P, Isachsen MM, Hoiseth A: Computed tomography of mucin-producing adenocarcinoma of the appendix presenting as a bladder tumor. Comput Assist Tomogr 1985, 9:566-567.
• [29]Gandhi VV, Nagral S: Pseudomyxoma peritonea: uncommon presentation. Indian J Surg 2012, 74:172-173.
• [30]Snyder TE, Vandivort MR: Mucinous cystadenocarcinoma of the appendix with pseudomyxoma peritonei presenting as total uterine prolapse. A case report. J Reprod Med 1992, 37:103-106.
• [31]Newman CM, Moran BJ: Pseudomyxoma peritonei presenting as recurrent rectal cancer: a preventable condition? Tech Coloproctol 2011, 15:89-90.
• [32]Koyama S, Tomimatsu T, Sawada K, Kanagawa T, Tsutsui T, Kimura T: Pseudomyxoma peritonei originating from colorectal cancer during pregnancy. J Obstet Gynaecol Res 2011, 37:254-258.
• [33]Abdu B, Hobgood D, Stallings S, Depasquale S: Incidental finding of pseudomyxoma peritonei at primary cesarean section. Am J Perinatol 2009, 26:633-635.
• [34]Cakmak A, Karakayali F, Bayar S, Unal E, Akyol C, Kocaoglu H: Pseudomyxoma retroperitonei presenting with a skin fistula. Turk J Gastroenterol 2009, 20:79-80.
• [35]Srinivasaiah N, Retnasingam G, Kasarneni R, Slater B: Pseudomyxoma peritonei: a rare presentation as an umbilical nodule. Ir J Med Sci 2009, 178:219-221.
• [36]Smeenk RM, Verwaal VJ, Zoetmulder FA: Pseudomyxoma peritonei. Cancer Treat Rev 2007, 33:138-145.
• [37]Kalu E, Croucher C: Appendiceal mucocele: a rare differential diagnosis of a cystic right adnexal mass. Arch Gynecol Obstet 2005, 271:86-88.
• [38]Gortchev G, Tomov S, Dimitrov D, Nanev V, Betova T: Appendiceal mucocele presenting as a right adnexal mass: a case report. Obstet Gynecol Int 2010., 2010doi:10.1155/2010/281053
• [39]Khan S, Patel AG, Jurkovic D: Incidental ultrasound diagnosis of pseudomyxoma peritonei in an asymptomatic woman. Ultrasound Obstet Gynecol 2002, 19:410-412.
• [40]Kreel L, Bydder GM: Computed tomography of fluid collections within the abdomen. J Comput Tomogr 1980, 4:105-115.
• [41]Sulkin TV, O’Neill H, Amin AI, Moran B: CT in pseudomyxoma peritonei: a review of 17 cases. Clin Radiol 2002, 57:608-613.
• [42]Buy JN, Malbec L, Ghossain MA, Guinet C, Ecoiffier J: Magnetic resonance imaging of pseudomyxoma peritonei. Eur J Radiol 1989, 9:115-118.
• [43]Matsuoka Y, Masumoto T, Suzuki K, Terada K, Ushimi T, Yokoyama Y, Abe K, Kamata N, Yasuno M, Hishima T: Pseudomyxoma retroperitonei. Eur Radiol 1999, 9:457-459.
• [44]Fairise A, Barbary C, Derelle A, Tissier S, Granger P, Marchal F, Laurent V: Regent D: [Mucocele of the appendix and pseudomyxoma peritonei]. J Radiol 2008, 89:751-762.
• [45]Yang QM, Bando E, Kawamura T, Tsukiyama G, Nemoto M, Yonemura Y, Furukawa H: The diagnostic value of PET-CT for peritoneal dissemination of abdominal malignancies. Gan To Kagaku Ryoho 2006, 33:1817-1821.
• [46]Passot G, Glehen O, Pellet O, Isaac S, Tychyj C, Mohamed F, Giammarile F, Gilly FN, Cotte E: Pseudomyxoma peritonei: role of 18 F-FDG PET in preoperative evaluation of pathological grade and potential for complete cytoreduction. Eur J Surg Oncol 2010, 36:315-323.
• [47]Stewart JH IV, Shen P, Levine EA: Intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: current status and future directions. Ann Surg Oncol 2005, 12:765-777.
• [48]Rohani P, Scotti SD, Shen P, Stewart JH, Russell GB, Cromer M, Levine EA: Use of FDG-PET imaging for patients with disseminated cancer of the appendix. Am Surg 2010, 76:1338-1344.
• [49]Carmignani CP, Hampton R, Sugarbaker CE, Chang D, Sugarbaker PH: Utility of CEA and CA 19–9 tumor markers in diagnosis and prognostic assessment of mucinous epithelial cancers of the appendix. J Surg Oncol 2004, 87:162-166.
• [50]Alexander-Sefre F, Chandrakumaran K, Banerjee S, Sexton R, Thomas JM, Moran B: Elevated tumour markers prior to complete tumour removal in patients with pseudomyxoma peritonei predict early recurrence. Colorectal Dis 2005, 7:382-386.
• [51]van Ruth S, Hart AA, Bonfrer JM, Verwaal VJ, Zoetmulder FA: Prognostic value of baseline and serial carcinoembryonic antigen and carbohydrate antigen 19.9 measurements in patients with pseudomyxoma peritonei treated with cytoreduction and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 2002, 9:961-967.
• [52]Baratti D, Kusamura S, Martinetti A, Seregni E, Laterza B, Oliva DG, Deraco M: Prognostic value of circulating tumor markers in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 2007, 14:2300-2308.
• [53]Chua TC, Chong CH, Liauw W, Zhao J, Morris DL: Inflammatory markers in blood and serum tumor markers predict survival in patients with epithelial appendiceal neoplasms undergoing surgical cytoreduction and intraperitoneal chemotherapy. Ann Surg 2012, 256:342-349.
• [54]Koh JL, Liauw W, Chua T, Morris DL: Carbohydrate antigen 19–9 (CA 19–9) is an independent prognostic indicator in pseudomyxoma peritonei post cytoreductive surgery and perioperative intraperitoneal chemotherapy. J Gastrointest Oncol 2013, 4:173-181.
• [55]Kusamura S, Hutanu I, Baratti D, Deraco M: Circulating tumor markers: predictors of incomplete cytoreduction and powerful determinants of outcome in pseudomyxoma peritonei. J Surg Oncol 2013, 108:1-8.
• [56]O’Connell JT, Hacker CM, Barsky SH: MUC2 is a molecular marker for pseudomyxoma peritonei. Mod Pathol 2002, 15:958-972.
• [57]Bibi R, Pranesh N, Saunders MP, Wilson MS, O’Dwyer ST, Stern PL, Renehan AG: A specific cadherin phenotype may characterise the disseminating yet non-metastatic behaviour of pseudomyxoma peritonei. Br J Cancer 2006, 95:1258-1264.
• [58]Semino-Mora C, Liu H, McAvoy T, Nieroda C, Studeman K, Sardi A, Dubois A: Pseudomyxoma peritonei: is disease progression related to microbial agents? A study of bacteria, MUC2 AND MUC5AC expression in disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. Ann Surg Oncol 2008, 15:1414-1423.
• [59]Flatmark K, Davidson B, Kristian A, Stavnes HT, Forsund M, Reed W: Exploring the peritoneal surface malignancy phenotype–a pilot immunohistochemical study of human pseudomyxoma peritonei and derived animal models. Hum Pathol 2010, 41:1109-1119.
• [60]Guo AT, Song X, Wei LX, Zhao P: Histological origin of pseudomyxoma peritonei in Chinese women: clinicopathology and immunohistochemistry. World J Gastroenterol 2011, 17:3531-3537.
• [61]Baratti D, Kusamura S, Nonaka D, Cabras AD, Laterza B, Deraco M: Pseudomyxoma peritonei: biological features are the dominant prognostic determinants after complete cytoreduction and hyperthermic intraperitoneal chemotherapy. Ann Surg 2009, 249:243-249.
• [62]Clement PB, Granai CO, Young RH, Scully RE: Endometriosis with myxoid change. A case simulating pseudomyxoma peritonei. Am J Surg Pathol 1994, 18:849-853.
• [63]Sugi Subramaniam RV, Karthikeyan VS, Sistla SC, Ali SM, Sistla S, Ram D, Sudhagar R: Melioidosis presenting as pseudomyxoma peritonei: yet another pretense of the great mimicker: an unreported entity. Surg Infect (Larchmt) 2013, 14:415-417.
• [64]Mirich DR, Gray RR, Grosman H: Abdominal plexiform neurofibromatosis simulating pseudomyxoma peritonei on computed tomography. J Comput Assist Tomogr 1989, 13:709-711.
• [65]Gough DB, Donohue JH, Schutt AJ, Gonchoroff N, Goellner JR, Wilson TO, Naessens JM, O’Brien PC, van Heerden JA: Pseudomyxoma peritonei. Long-term patient survival with an aggressive regional approach. Ann Surg 1994, 219:112-119.
• [66]Miner TJ, Shia J, Jaques DP, Klimstra DS, Brennan MF, Coit DG: Long-term survival following treatment of pseudomyxoma peritonei: an analysis of surgical therapy. Ann Surg 2005, 241:300-308.
• [67]Jarvinen P, Jarvinen HJ, Lepisto A: Survival of patients with pseudomyxoma peritonei treated by serial debulking. Colorectal Dis 2010, 12:868-872.
• [68]Sugarbaker PH: Cytoreductive surgery and intraperitoneal chemotherapy with peritoneal spread of cystadenocarcinoma. Eur J Surg Suppl = Acta chirurgica Supplement 1991, 561:75-82.
• [69]Sugarbaker PH: Cytoreductive surgery and peri-operative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome. Eur J Surg Oncol 2001, 27:239-243.
• [70]Hadi R, Saunders V, Utkina O, Clingan P, Kam P, Links M, Morris DL: Review of patients with peritoneal malignancy treated with peritonectomy and heated intraperitoneal chemotherapy. ANZ J Surg 2006, 76:156-161.
• [71]Yan TD, Links M, Xu ZY, Kam PC, Glenn D, Morris DL: Cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei from appendiceal mucinous neoplasms. Br J Surg 2006, 93:1270-1276.
• [72]Chua TC, Yan TD, Smigielski ME, Zhu KJ, Ng KM, Zhao J, Morris DL: Long-term survival in patients with pseudomyxoma peritonei treated with cytoreductive surgery and perioperative intraperitoneal chemotherapy: 10 years of experience from a single institution. Ann Surg Oncol 2009, 16:1903-1911.
• [73]Chua TC, Liauw W, Morris DL: The St George Hospital peritoneal surface malignancy program–where are we now? ANZ J Surg 2009, 79:416-418.
• [74]Saxena A, Yan TD, Chua TC, Morris DL: Critical assessment of risk factors for complications after cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei. Ann Surg Oncol 2010, 17:1291-1301.
• [75]Chua TC, Baker B, Yan TD, Zhao J, Morris DL: Palliative effects of an incomplete cytoreduction combined with perioperative intraperitoneal chemotherapy. Am J Clin Oncol 2010, 33:568-571.
• [76]Chua TC, Al-Zahrani A, Saxena A, Liauw W, Zhao J, Morris DL: Secondary cytoreduction and perioperative intraperitoneal chemotherapy after initial debulking of pseudomyxoma peritonei: a study of timing and the impact of malignant dedifferentiation. J Am Coll Surg 2010, 211:526-535.
• [77]Chua TC, Martin S, Saxena A, Liauw W, Yan TD, Zhao J, Lok I, Morris DL: Evaluation of the cost-effectiveness of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (peritonectomy) at the St George Hospital peritoneal surface malignancy program. Ann Surg 2010, 251:323-329.
• [78]Chua TC, Al-Zahrani A, Saxena A, Glenn D, Liauw W, Zhao J, Morris DL: Determining the association between preoperative computed tomography findings and postoperative outcomes after cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei. Ann Surg Oncol 2011, 18:1582-1589.
• [79]Chua TC, Liauw W, Zhao J, Morris DL: Upfront compared to delayed cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei is associated with considerably lower perioperative morbidity and recurrence rate. Ann Surg 2011, 253:769-773.
• [80]Chua TC, Liauw W, Morris DL: Early recurrence of pseudomyxoma peritonei following treatment failure of cytoreductive surgery and perioperative intraperitoneal chemotherapy is indicative of a poor survival outcome. Int J Colorectal Dis 2012, 27:381-389.
• [81]Kirby R, Liauw W, Zhao J, Morris D: Quality of life study following cytoreductive surgery and intraperitoneal chemotherapy for pseudomyxoma peritonei including redo procedures. Int J Surg Oncol 2013, 2013:461041.
• [82]Sugarbaker PH, Chang D: Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol 1999, 6:727-731.
• [83]Deraco M, Baratti D, Inglese MG, Allaria B, Andreola S, Gavazzi C, Kusamura S: Peritonectomy and intraperitoneal hyperthermic perfusion (IPHP): a strategy that has confirmed its efficacy in patients with pseudomyxoma peritonei. Ann Surg Oncol 2004, 11:393-398.
• [84]Loungnarath R, Causeret S, Bossard N, Faheez M, Sayag-Beaujard AC, Brigand C, Gilly F, Glehen O: Cytoreductive surgery with intraperitoneal chemohyperthermia for the treatment of pseudomyxoma peritonei: a prospective study. Dis Colon Rectum 2005, 48:1372-1379.
• [85]Murphy EM, Sexton R, Moran BJ: Early results of surgery in 123 patients with pseudomyxoma peritonei from a perforated appendiceal neoplasm. Dis Colon Rectum 2007, 50:37-42.
• [86]Smeenk RM, Verwaal VJ, Antonini N, Zoetmulder FA: Survival analysis of pseudomyxoma peritonei patients treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg 2007, 245:104-109.
• [87]Moran B, Baratti D, Yan TD, Kusamura S, Deraco M: Consensus statement on the loco-regional treatment of appendiceal mucinous neoplasms with peritoneal dissemination (pseudomyxoma peritonei). J Surg Oncol 2008, 98:277-282.
• [88]Elias D, Gilly F, Quenet F, Bereder JM, Sideris L, Mansvelt B, Lorimier G, Glehen O: Pseudomyxoma peritonei: a French multicentric study of 301 patients treated with cytoreductive surgery and intraperitoneal chemotherapy. Eur J Surg Oncol 2010, 36:456-462.
• [89]Andreasson H, Graf W, Nygren P, Glimelius B, Mahteme H: Outcome differences between debulking surgery and cytoreductive surgery in patients with Pseudomyxoma peritonei. Eur J Surg Oncol 2012, 38:962-968.
• [90]Dayal S, Taflampas P, Riss S, Chandrakumaran K, Cecil TD, Mohamed F, Moran BJ: Complete cytoreduction for pseudomyxoma peritonei is optimal but maximal tumor debulking may be beneficial in patients in whom complete tumor removal cannot be achieved. Dis Colon Rectum 2013, 56:1366-1372.
• [91]Kuijpers AM, Mirck B, Aalbers AG, Nienhuijs SW, de Hingh IH, Wiezer MJ, van Ramshorst B, van Ginkel RJ, Havenga K, Bremers AJ, de Wilt JH, Te Velde EA, Verwaal VJ: Cytoreduction and HIPEC in the Netherlands: nationwide long-term outcome following the Dutch protocol. Ann Surg Oncol 2013, 20:4224-4230.
• [92]McBride K, McFadden D, Osler T: Improved survival of patients with pseudomyxoma peritonei receiving intraperitoneal chemotherapy with cytoreductive surgery: a systematic review and meta-analysis. J Surg Res 2013, 183:246-252.
• [93]Raj J, Urban LM, ReMine SG, Raj PK: Laparoscopic management of pseudomyxoma peritonei secondary to adenocarcinoma of the appendix. J Laparoendosc Adv Surg Tech A 1999, 9:299-303.
• [94]Fish R, Selvasekar C, Crichton P, Wilson M, Fulford P, Renehan A, O’Dwyer S: Risk-reducing laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for low-grade appendiceal mucinous neoplasm: early outcomes and technique. Surg Endosc 2014, 28:341-345.
• [95]Berkovic P, van de Voorde L, De Meerleer G, Delrue L, Speleers B, Van Belle S, Vandecasteele K: Whole abdominopelvic radiotherapy in the palliative treatment of pseudomyxoma peritonei. Strahlenther Onkolo: Organ der Deutschen Rontgengesellschaft [et al.] 2014, 190:223-228.
• [96]Green N, Gancedo H, Smith R, Bernett G: Pseudomyxoma peritonei-nonoperative management and biochemical findings. A case report. Cancer 1975, 36:1834-1837.
• [97]Piver MS, Lele SB, Patsner B: Pseudomyxoma peritonei: possible prevention of mucinous ascites by peritoneal lavage. Obstet Gynecol 1984, 64:95S-96S.
• [98]Machado MA, Rodrigues JG, Laurino RM, Garrido Junior A, Pinotti HW: [Conservative treatment of pseudomyxoma peritonei]. Rev Hosp Clin Fac Med Sao Paulo 1993, 48:301-304.
• [99]Pillai K, Akhter J, Chua TC, Morris DL: Mucolysis by ascorbic acid and hydrogen peroxide on compact mucin secreted in pseudomyxoma peritonei. J Surg Res 2012, 174:e69-73.
• [100]Pillai K, Akhter J, Chua TC, Morris DL: Potential mucolytic agents for mucinous ascites from pseudomyxoma peritonei. Invest New Drugs 2012, 30:2080-2086.
• [101]Gilbreath JJ, Semino-Mora C, Friedline CJ, Liu H, Bodi KL, McAvoy TJ, Francis J, Nieroda C, Sardi A, Dubois A, Lazinski DW, Camilli A, Testerman TL, Merrell DS: A core microbiome associated with the peritoneal tumors of pseudomyxoma peritonei. Orphanet J Rare Dis 2013, 8:105. BioMed Central Full Text
• [102]Semino-Mora C, Testerman TL, Liu H, Whitmire JM, Studeman K, Jia Y, McAvoy TJ, Francis J, Nieroda C, Sardi A, Merrell DS, Dubois A: Antibiotic treatment decreases microbial burden associated with pseudomyxoma peritonei and affects beta-catenin distribution. Clin Cancer Res 2013, 19:3966-3976.
• [103]Choudry HA, Mavanur A, O’Malley ME, Zeh HJ, Guo Z, Bartlett DL: Chronic anti-inflammatory drug therapy inhibits gel-forming mucin production in a murine xenograft model of human pseudomyxoma peritonei. Ann Surg Oncol 2012, 19:1402-1409.
• [104]Shetty S, Natarajan B, Thomas P, Govindarajan V, Sharma P, Loggie B: Proposed classification of pseudomyxoma peritonei: influence of signet ring cells on survival. Am Surg 2013, 79:1171-1176.
• [105]Solkar MH, Akhtar NM, Khan Z, Parker MC: Pseudomyxoma extraperitonei occurring 35 years after appendicectomy: a case report and review of literature. World J Surg Oncol 2004, 2:19. BioMed Central Full Text
• [106]Thompson MA, Ashton RW, Pitot HC: Mucinous appendiceal adenocarcinoma presenting 5 years after appendectomy. Ann Intern Med 2004, 140:W33.
• [107]Vana J, Adamicova K, Johanes R, Zacharova O, Ammerova E, Solek R: [Appendiceal mucocele causing pseudomyxoma peritonei]. Zentralblatt fur Chirurgie 2005, 130:177-180.
• [108]Ruiz-Tovar J, Teruel DG, Castineiras VM, Dehesa AS, Quindos PL, Molina EM: Mucocele of the appendix. World J Surg 2007, 31:542-548.
• [109]Taii A, Sakagami J, Shinoda M, Taniguchi H, Tosa M, Baba T, Motoyoshi T, Ito R, Mitsufuji S, Kataoka K, Okanoue T: Pseudomyxoma peritonei occurring after an uneventful 23 years interval from appendectomy. Intern Med 2007, 46:1109-1112.
• [110]Spiliotis J, Efstathiou E, Halkia E, Vaxevanidou A, Datsis A, Sugarbaker P: The influence of tumor cell entrapment phenomenon on the natural history of Pseudomyxoma peritonei syndrome. Hepatogastroenterology 2012, 59:705-708.
• [111]Gum JR Jr: Mucin genes and the proteins they encode: structure, diversity, and regulation. Am J Respir Cell Mol Biol 1992, 7:557-564.
• [112]Rose MC, Voynow JA: Respiratory tract mucin genes and mucin glycoproteins in health and disease. Physiol Rev 2006, 86:245-278.
• [113]Williams OW, Sharafkhaneh A, Kim V, Dickey BF, Evans CM: Airway mucus: from production to secretion. Am J Respir Cell Mol Biol 2006, 34:527-536.
• [114]Hollingsworth MA, Swanson BJ: Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer 2004, 4:45-60.
• [115]Rachagani S, Torres MP, Moniaux N, Batra SK: Current status of mucins in the diagnosis and therapy of cancer. Biofactors 2009, 35:509-527.
• [116]Kufe DW: Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer 2009, 9:874-885.
• [117]Cone RA: Barrier properties of mucus. Adv Drug Deliv Rev 2009, 61:75-85.
• [118]Lievin-Le Moal V, Servin AL: The front line of enteric host defense against unwelcome intrusion of harmful microorganisms: mucins, antimicrobial peptides, and microbiota. Clin Microbiol Rev 2006, 19:315-337.
• [119]McCracken VJ, Lorenz RG: The gastrointestinal ecosystem: a precarious alliance among epithelium, immunity and microbiota. Cell Microbiol 2001, 3:1-11.
• [120]Dharmani P, Srivastava V, Kissoon-Singh V, Chadee K: Role of intestinal mucins in innate host defense mechanisms against pathogens. J Innate Immun 2009, 1:123-135.
• [121]Johansson ME, Larsson JM, Hansson GC: The two mucus layers of colon are organized by the MUC2 mucin, whereas the outer layer is a legislator of host-microbial interactions. Proc Natl Acad Sci U S A 2011, 108(Suppl 1):4659-4665.
• [122]Mall AS, Chirwa N, Govender D, Lotz Z, Tyler M, Rodrigues J, Kahn D, Goldberg P: MUC2, MUC5AC and MUC5B in the mucus of a patient with pseudomyxoma peritonei: biochemical and immunohistochemical study. Pathol Int 2007, 57:537-547.
• [123]Mall AS, Lotz Z, Tyler M, Goldberg P, Rodrigues J, Kahn D, Chirwa N, Govender D: Immunohistochemical and biochemical characterization of mucin in pseudomyxoma peritonei: a case study. Case Rep Gastroenterol 2011, 5:5-16.
• [124]Sheehan JK, Richardson PS, Fung DC, Howard M, Thornton DJ: Analysis of respiratory mucus glycoproteins in asthma: a detailed study from a patient who died in status asthmaticus. Am J Respir Cell Mol Biol 1995, 13:748-756.
• [125]Sheehan JK, Howard M, Richardson PS, Longwill T, Thornton DJ: Physical characterization of a low-charge glycoform of the MUC5B mucin comprising the gel-phase of an asthmatic respiratory mucous plug. Biochem J 1999, 338(Pt 2):507-513.
• [126]Mohamed F, Gething S, Haiba M, Brun EA, Sugarbaker PH: Clinically aggressive pseudomyxoma peritonei: a variant of a histologically indolent process. J Surg Oncol 2004, 86:10-15.
• [127]Kinkor Z, Michal M: [Syndrome of pseudomyxoma peritonei–description of three cases and survey of the problem]. Ceska Gynekol 2005, 70:67-72.
• [128]Nonaka D, Kusamura S, Baratti D, Casali P, Younan R, Deraco M: CDX-2 expression in pseudomyxoma peritonei: a clinicopathological study of 42 cases. Histopathology 2006, 49:381-387.
• [129]Ferreira CR, Carvalho JP, Soares FA, Siqueira SA, Carvalho FM: Mucinous ovarian tumors associated with pseudomyxoma peritonei of adenomucinosis type: immunohistochemical evidence that they are secondary tumors. Int J Gynecol Cancer 2008, 18:59-65.
• [130]Chang MS, Byeon SJ, Yoon SO, Kim BH, Lee HS, Kang GH, Kim WH, Park KJ: Leptin, MUC2 and mTOR in appendiceal mucinous neoplasms. Pathobiology 2012, 79:45-53.
• [131]Li JD, Feng W, Gallup M, Kim JH, Gum J, Kim Y, Basbaum C: Activation of NF-kappaB via a Src-dependent Ras-MAPK-pp90rsk pathway is required for Pseudomonas aeruginosa-induced mucin overproduction in epithelial cells. Proc Natl Acad Sci U S A 1998, 95:5718-5723.
• [132]Perrais M, Pigny P, Copin MC, Aubert JP, Van Seuningen I: Induction of MUC2 and MUC5AC mucins by factors of the epidermal growth factor (EGF) family is mediated by EGF receptor/Ras/Raf/extracellular signal-regulated kinase cascade and Sp1. J Biol Chem 2002, 277:32258-32267.
• [133]Orlowski RZ, Baldwin AS Jr: NF-kappaB as a therapeutic target in cancer. Trends Mol Med 2002, 8:385-389.
• [134]Choudry HA, O’Malley ME, Guo ZS, Zeh HJ, Bartlett DL: Mucin as a therapeutic target in pseudomyxoma peritonei. J Surg Oncol 2012, 106:911-917.
• [135]Enss ML, Cornberg M, Wagner S, Gebert A, Henrichs M, Eisenblatter R, Beil W, Kownatzki R, Hedrich HJ: Proinflammatory cytokines trigger MUC gene expression and mucin release in the intestinal cancer cell line LS180. Inflamm Res 2000, 49:162-169.
• [136]Kim YD, Kwon EJ, Kwon TK, Baek SH, Song SY, Suh JS: Regulation of IL-1beta-mediated MUC2 gene in NCI-H292 human airway epithelial cells. Biochem Biophys Res Commun 2000, 274:112-116.
• [137]Iwashita J, Sato Y, Sugaya H, Takahashi N, Sasaki H, Abe T: mRNA of MUC2 is stimulated by IL-4, IL-13 or TNF-alpha through a mitogen-activated protein kinase pathway in human colon cancer cells. Immunol Cell Biol 2003, 81:275-282.
• [138]Kai H, Yoshitake K, Hisatsune A, Kido T, Isohama Y, Takahama K, Miyata T: Dexamethasone suppresses mucus production and MUC-2 and MUC-5 AC gene expression by NCI-H292 cells. Am J Physiol 1996, 271:L484-L488.
• [139]Schoneveld OJ, Gaemers IC, Lamers WH: Mechanisms of glucocorticoid signalling. Biochim Biophys Acta 2004, 1680:114-128.
• [140]Okudaira K, Kakar S, Cun L, Choi E, Wu Decamillis R, Miura S, Sleisenger MH, Kim YS, Deng G: MUC2 gene promoter methylation in mucinous and non-mucinous colorectal cancer tissues. Int J Oncol 2010, 36:765-775.
• [141]Aslam F, Palumbo L, Augenlicht LH, Velcich A: The Sp family of transcription factors in the regulation of the human and mouse MUC2 gene promoters. Cancer Res 2001, 61:570-576.
• [142]Chua TC, Akther J, Yao P, Morris DL: In vivo model of pseudomyxoma peritonei for novel candidate drug discovery. Anticancer Res 2009, 29:4051-4055.
• [143]Akhter J, Yao P, Johnson LA, Riordan SM, Morris DL: A new peritoneal carcinomatosis model in cyclosporine immunosuppressed rats. Anticancer Res 2008, 28:105-108.
• [144]Bromelain. Monograph Altern Med Rev 2010, 15:361-368.
• [145]N-acetylcysteine Altern Med Rev 2000, 5:467-471.
• [146]Amini A, Ehteda A, Masoumi Moghaddam S, Akhter J, Pillai K, Morris DL: Cytotoxic effects of bromelain in human gastrointestinal carcinoma cell lines (MKN45, KATO-III, HT29-5F12, and HT29-5M21). Onco Targets Ther 2013, 2013:403-409.
• [147]Pillai K, Akhter J, Chua TC, Morris DL: Anticancer property of bromelain with therapeutic potential in malignant peritoneal mesothelioma. Cancer Invest 2013, 31:241-250.
• [148]Pillai K, Ehteda A, Akhter J, Chua TC, Morris DL: Anticancer effect of bromelain with and without cisplatin or 5-FU on malignant peritoneal mesothelioma cells. Anti-cancer drugs 2014, 25:150-160.
• [149]Pillai K, Akhter J, Chua TC, Morris DL: A formulation for in situ lysis of mucin secreted in pseudomyxoma peritonei. Int J Cancer 2014, 134:478-486.